GlobeNewswire Inc | Nov 24, 2020 07:00AM EST

November 24, 2020

NEW YORK, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Mark Pruzanski, M.D., President and Chief Executive Officer, Sandip Kapadia, Chief Financial Officer, and Gail Cawkwell, M.D., Ph.D., SVP, Medical Affairs, Safety and Pharmacovigilance of Intercept, will participate in a fireside chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference on Tuesday, December 1, 2020 from 3:30 3:55 p.m. ET.

A live webcast of the event will be available on the investor page of Intercepts website at http://ir.interceptpharma.com. An audio archive of the webcast will also be available on Intercepts website for approximately two weeks.

About Intercept

Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). Founded in 2002 inNew York, Intercept has operations inthe United States,EuropeandCanada. For more information, please visit www.interceptpharma.com or connect with the company on Twitter and LinkedIn.

Contact

For more information about Intercept, please contact:

Investor inquiries: investors@interceptpharma.com

Media inquiries: media@interceptpharma.com